Prospective evaluation of KRAS, NRAS, BRAF, and PI3KCA mutation screening for patient enrolment in AGITG ICECREAM (Irinotecan Cetaximab Evaluation and the Cetuximab Response Evaluation among Patients with G13D Mutation) trial in metastatic colorectal cancer (mCRC).

Waring, Paul Michael; Desai, Jayesh; Rudzki, Zbigniew Barney; Wilson, Kate; Gebskl, Val; Nott, Louise M; Karapetls, Christos Statics; Khasraw, Mustafa; Underhill, Craig; Pavlakis, Nick; Chantrill, Lorraine A; Shapiro, Jeremy David; Segelov, Eva

Prospective evaluation of KRAS, NRAS, BRAF, and PI3KCA mutation screening for patient enrolment in AGITG ICECREAM (Irinotecan Cetaximab Evaluation and the Cetuximab Response Evaluation among Patients with G13D Mutation) trial in metastatic colorectal cancer (mCRC).

conference contribution

posted on 2022-11-25, 03:56 authored by Paul Michael Waring, Jayesh Desai, Zbigniew Barney Rudzki, Kate Wilson, Val Gebskl, Louise M Nott, Christos Statics Karapetls, Mustafa Khasraw, Craig Underhill, Nick Pavlakis, Lorraine A Chantrill, Jeremy David Shapiro, Eva Segelov

Prospective evaluation of KRAS, NRAS, BRAF, and PI3KCA mutation screening for patient enrolment in AGITG ICECREAM (Irinotecan Cetaximab Evaluation and the Cetuximab Response Evaluation among Patients with G13D Mutation) trial in metastatic colorectal cancer (mCRC).

History

Related Materials

1.
DOI - Is version of https://doi.org/10.1200/jco.2014.32.15_suppl.e14536

Location

Chicago, IL

Language

English

Author URL

https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000358613200307&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a045e4b2bb1f2b747c68c720ec8913b7

Publication classification

E3.1 Extract of paper

Volume

32

Start date

2014-05-30

End date

2014-06-03

ISSN

0732-183X

eISSN

1527-7755

Title of proceedings

JOURNAL OF CLINICAL ONCOLOGY

Event

50th Annual Meeting of the American-Society-of-Clinical-Oncology

Issue

15

Publisher

AMER SOC CLINICAL ONCOLOGY

Usage metrics

Keywords

Science & Technology Life Sciences & Biomedicine Oncology

Prospective evaluation of KRAS, NRAS, BRAF, and PI3KCA mutation screening for patient enrolment in AGITG ICECREAM (Irinotecan Cetaximab Evaluation and the Cetuximab Response Evaluation among Patients with G13D Mutation) trial in metastatic colorectal cancer (mCRC).

History

Related Materials

Location

Language

Author URL

Publication classification

Volume

Start date

End date

ISSN

eISSN

Title of proceedings

Event

Issue

Publisher

Usage metrics

Categories

Keywords

Licence

Exports